U.S. Physical Therapy, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a USPH research report →
Range $90 – $102
Price Chart
About the company
U. S. Physical Therapy, Inc.
- CEO
- Christopher J. Reading
- IPO
- 1992
- Employees
- 6,374
- HQ
- Houston, TX, US
Get TickerSpark's AI analysis on USPH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.43B
- P/E
- -69.87
- Fwd P/E
- 33.29
- PEG
- 0.45
- P/S
- 1.68
- P/B
- 3.28
- EV/EBITDA
- 17.74
- Div Yield
- 1.95%
- Gross Margin
- 18.57%
- Op Margin
- 10.03%
- Net Margin
- -0.27%
- ROE
- -0.49%
- ROIC
- 5.12%
Latest fiscal year · YoY change
- Revenue
- $780.99M+16.3%
- Gross Profit
- $157.34M+27.0%
- Op Income
- $80.43M
- Net Income
- $15.06M-43.1%
- EPS
- $1.42-22.8%
- OCF Growth
- +0.2%
- FCF Growth
- -7.2%
- 52W High
- $101.80
- 52W Low
- $58.19
- 50D MA
- $87.71
- 200D MA
- $77.52
- Beta
- 1.13
- RSI (14)
- 55
- Avg Volume
- 185.59K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
U.S. Physical Therapy delivered a solid quarter with 13% revenue growth, improved margins, and continued hospital-affiliation momentum, while higher employee health costs remained a major offset.· November 5, 2026
- Total revenue rose 13% to $223 million, with adjusted EPS of $0.80, up $0.14 year over year.
- Patient visits increased 8% to 1.68 million and daily visits per clinic rose to 33 from 32 a year ago.
- Hospital affiliations were a major driver: revenue from these partnerships exceeded $25 million and hospital revenue rose to more than 13% of revenue from less than 5% in Q2.
- Adjusted PT margin improved to 19%, but management said employee benefit costs reduced margin by about 150 basis points and could remain a Q4 headwind.
- Management reaffirmed full-year EBITDA guidance of $102 million to $106 million and said Q4 will be the first full quarter with both hospital partnerships fully loaded.
Third-quarter 2026 revenue was $223 million, up 13% year over year, with comparable revenue up 7%. Physical therapy revenue was $190 million, up 13%, while IIP revenue was $33 million, up 14% (8% excluding January acquisitions). Patient visits were 1.68 million, up 8%, and revenue per visit was $111, up $5 year over year. Adjusted PT margin was 19%, up 60 basis points; IIP margin was 22%, up 230 basis points; adjusted corporate expenses were 8% of revenue, down 80 basis points. Adjusted net income was $12 million, up $2 million, and adjusted EPS was $0.80, up $0.14. On a GAAP basis, net income attributable to USPH shareholders was $11 million versus $13 million last year, and GAAP loss per share was $1.04 versus EPS of $0.48. Cash ended at $38 million, credit facility borrowings were $247 million, year-to-date operating cash flow was $64 million, and the company reaffirmed full-year EBITDA guidance of $102 million to $106 million.
Chris Reading emphasized strong operational execution, record monthly visit volumes for 27 straight months, and the successful onboarding of the Metro New York and Gulf Coast hospital partnerships. He framed the quarter as a pivotal point for the company, saying Medicare reimbursement cuts are behind it and that the business now has better net rates, more margin opportunity, and continued volume strength ahead. His tone was upbeat but measured, repeatedly noting that some margin factors, especially self-insured health costs, are outside management’s direct control.
Nchacha Etta said the quarter showed double-digit revenue growth and margin expansion, which gave the company confidence to reaffirm full-year EBITDA guidance. He highlighted revenue of $223 million, adjusted EPS of $0.80, PT margin of 19%, IIP margin of 22%, and adjusted corporate expenses at 8% of revenue. On the balance sheet, he noted $38 million of cash, $247 million of borrowings, $64 million of year-to-date operating cash flow, and a capital allocation mix that included $36 million for acquisitions, $23 million for minority interests, $21 million in dividends, and $19 million in share repurchases. He also said employee insurance claims were $7 million higher year to date and $2 million over budget in Q3, but that labor reductions and discretionary spending cuts should help in future periods.
Analysts focused heavily on the hospital affiliations, asking how much Q4 could improve now that both partnerships will be in place for the full quarter. Management said it would not give a numeric Q4 ramp, but confirmed that Q4 will be the first full quarter with both partnerships fully loaded and that the company is ahead of where it expected to be on the Metro side. Questions also centered on the physician fee schedule and the IPSI/IPIC-related methodology change; management estimated the base schedule changes look roughly 0.7% positive for next year and said the modifier phaseout beginning in 2027 should be a meaningful multiyear tailwind. Analysts asked about workers’ compensation strength and IIP growth, and management said workers’ comp has been a major focus for three-plus years, while IIP remains supported by solid pipelines and repeatable injury-prevention services, though Q4 is typically seasonally softer.
The call showed that volume trends remain strong, with record monthly visits, rising productivity per clinic, and higher reimbursement from hospital affiliations all moving in the right direction. Management also sounded confident that the hospital partnership model still has room to expand, with additional de novo and tuck-in opportunities, and that the CMS methodology change could provide a multiyear reimbursement tailwind.
The biggest headwind is still employee health care cost inflation, which management said was $7 million higher year to date and could stay elevated in Q4. Management also warned that some of the margin benefits from labor reductions and hospital onboarding may take time to fully show through, and injury prevention is expected to be seasonally softer in the fourth quarter.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.4%
- Shares Outstanding
- 14.93M
- Float Shares
- 14.54M
of shares held by institutions
222 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for USPH, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Buy | Jul 16, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | May 20, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Apr 17, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jan 29, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Oct 17, 24 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Sep 16, 24 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | May 24, 23 | Filing → |
| Donna ShalalaHouse · FL27 | Sell | Jun 24, 19 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 2.23M | ▼ 37.83K |
| Vanguard Group Inc | 1.09M | ▲ 15.71K |
| Neuberger Berman Group LLC | 980.47K | ▲ 381.57K |
| Copeland Capital Management, LLC | 940.53K | ▲ 98.98K |
| Bahl & Gaynor LLC | 889.26K | ▲ 27.69K |
| State Street Corp | 719.46K | ▲ 12.27K |
| Morgan Stanley | 667.01K | ▼ 31.68K |
| William Blair Investment Management, LLC | 659.51K | ▲ 222.51K |
| Vanguard Capital Management LLC | 606.47K | ▼ 67.72K |
| American Century Companies Inc | 555.72K | ▼ 3.09K |
| Dimensional Fund Advisors LP | 531.57K | ▲ 17.65K |
| Kayne Anderson Rudnick Investment Management LLC | 522.87K | ▼ 323.80K |
Held by 295 ETFs
Biggest fund positions in USPH by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | REEVE GRAHAM D. | sell | 1,792 |
| Oct 1, 26 | Davis Myra | other | 1,210 |
| Oct 1, 26 | Davis Myra | other | 0 |
| Sep 14, 26 | Etta Nchacha | other | 6,831 |
| Sep 11, 26 | Minan Peter Francis | buy | 5.27 |
| Jun 12, 26 | Minan Peter Francis | buy | 0.87 |
| Sep 1, 26 | Etta Nchacha | other | 0 |
| Aug 20, 26 | Williams Eric Joseph | other | 714 |
| Aug 20, 26 | CURTIS JASON TRAVIS | other | 40 |
| Aug 20, 26 | Binstein Richard | other | 450 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our USPH coverage
Recent articles, reports, and earnings notes.
No research on USPH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate USPH report →U.S. Physical Therapy Presented at the 18th Annual Southwest IDEAS Conference
businesswire.com · Nov 19
U.S. Physical Therapy, Inc. $USPH Position Reduced by CenterBook Partners LP
defenseworld.net · Nov 9
U.S. Physical Therapy Q3 Earnings Call Highlights
marketbeat.com · Nov 7
U.S. Physical Therapy (NYSE:USPH) Hits New 52-Week High Following Earnings Beat
defenseworld.net · Nov 6
U.S. Physical Therapy, Inc. (USPH) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
Here's What Key Metrics Tell Us About U.S. Physical Therapy (USPH) Q3 Earnings
zacks.com · Nov 4
U.S. Physical Therapy (USPH) Tops Q3 Earnings and Revenue Estimates
zacks.com · Nov 4
USPH Reports Third Quarter 2026 Results, Record High Visits and Revenue Per Visit
businesswire.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.